Clinical trial completion rates decline during COVID-19 pandemic
|sciencedaily.com 07 Apr 2021 at 18:00|
Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected clinical researchers ability to finish trials. Study completion rates dropped worldwide between 13% and 23%, depending on the type of research sponsor and geographic location, between April and October 2020.
Researchers previously reported that more than 80% of clinical trials suspended between March 1 and April 26, 2020, noted the pandemic as their chief reason for halting activity. Patient enrollment in studies was lower in April 2020, compared to April 2019. Arthur Berg, associate professor of public health sciences, and Nour Hawila, a biostatistics doctoral candidate, investigated how these trends may have affected the completion of clinical trials.
The researchers examined more than 117,000 trials in the United States, Europe, Asia and other regions to study whether the pandemic affected clinical research. Their goal was to assess how the pandemic s mitigation efforts and financial setbacks may have contributed to decreased clinical trial enrollment and completion.
"The pandemic has made it more difficult for researchers to recruit and follow up on patients in clinical trials," said Hawila, a research assistant from the Department of Public Health Sciences. "This analysis revealed that the impact was substantial -- particularly for trials funded by government, academic or medical entities."
Hawila and Berg analyzed data from ClinicalTrials.gov, a website that contains information on the status of thousands of clinical trials in the U.S. Pre-COVID-19 enrollment and completion data was pulled from March 2017 to February 2020. The post-COVID-19 period was defined as April through October 2020.
However, some regions fared better than others during the pandemic. Egypt experienced an increase in both submitted (69%) and completed (73%) clinical trials. Berg explained that the rise is likely in response to the country s recent parliamentary bill governing medical research.
"Clinical research response to the pandemic has been robust," said Berg, a Penn State Cancer Institute researcher and biostatistics doctoral program director. "But the impact of the pandemic on other types of clinical trials will be felt for decades to come. However, as demonstrated in Egypt, timely governmental action may be able to make a difference in reversing the pandemic s impact on research."
Materials provided by Penn State . Original written by Zachary Sweger. Note: Content may be edited for style and length.
Penn State. "Clinical trial completion rates decline during COVID-19 pandemic." ScienceDaily. ScienceDaily, 7 April 2021.
Penn State. "Clinical trial completion rates decline during COVID-19 pandemic." ScienceDaily. www.sciencedaily.com/releases/2021/04/210407174310.htm (accessed April 7, 2021).
Dec. 3, 2020 New research has found that Chicago neighborhoods with barriers to social distancing, including limited access to broadband internet and low rates of health insurance, had more COVID-19 deaths in ...
Nov. 5, 2020 Research shows that Japan s noncompulsory state of emergency generally succeeded in reducing human movement. A recent study used mobile phone location data for January-April 2020 to record and ...
Oct. 14, 2020 Scientists have found that particulate matter concentrations in China dropped by an unprecedented 29.7 percent, and by 17.1 percent in parts of Europe, during lockdowns that took place between Feb. 1 ...
Apr. 30, 2016 Although the publication of results of clinical trials carried out in the USA within 12 months of their completion has been mandatory since 2007, an astoundingly high number of Phase III radiotherapy ...